How do you put a price on COVID-19 treatment?
Kellogg expert to discuss medical ethics and risks of pricing treatment too low in May 21 webinar
In the midst of a global pandemic, balancing medical ethics with business finances becomes uniquely challenging. If COVID-19 drug treatments are priced too high, it propels health disparities, but if they are priced too low, it discourages medical innovation at the time when we need it most, says health care economist Craig Garthwaite.
Garthwaite, director of the Program on Healthcare at Northwestern University’s Kellogg School of Management, will explore drug pricing strategy and the business of health care in a webinar titled “Pharma and the Pandemic – Lessons for the Future.”
The webinar will be held at noon CDT on Thursday, May 21. Media interested in joining the webinar or who wish to interview Garthwaite should RSVP online and email Kayla Stoner at email@example.com.
The webinar will be recorded and will be available online after the event.
Interview the Experts
Health care economist
Garthwaite is an applied economist whose research examines the business of health care with a focus on the interaction between private firms and public policies. His recent work has focused on private sector effects of the Affordable Care Act, economic effects of social insurance programs such as Medicaid and the responses of nonprofit hospitals to financial shocks.
Garthwaite is the Herman R. Smith Research Professor in Hospital and Health Services, an associate professor of strategy and director of the Program on Healthcare at Kellogg.